Abstract #132: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

The 63rd ASH Annual Meeting and Exposition – December 11-14, 2021